Novartis seeks nod for 50 drugs
By Zhou Wenting in Shanghai | China Daily | Updated: 2019-07-05 08:06
Company plans to tap unmet medical needs with innovative NDAs in China
Swiss pharmaceutical giant Novartis AG plans to submit applications for 50 innovative drugs focusing on unmet medical needs in China by 2023, riding the wave of streamlined and accelerated new drug approvals in the country.
Most of the drugs will target major diseases plaguing Chinese patients such as cardiovascular, eye and respiratory diseases, and tumors, John Tsai, head of global drug development and chief medical officer for Novartis, said in an interview with China Daily in Shanghai on Thursday.
Photo
